Unveiling the Therapeutic Potential of Nirmatrelvir–Ritonavir (NMV/r) in Real-World COVID-19 Data: A Call for Further Research and Evaluation

Unveiling the Therapeutic Potential of Nirmatrelvir–Ritonavir (NMV/r) in Real-World COVID-19 Data: A Call for Further Research and Evaluation

Saved in:

Bibliographic Details
Main Authors:	Sora Yasri, Viroj Wiwanitkit
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-10-01
Series:	Dr. Sulaiman Al Habib Medical Journal
Online Access:	https://journals.lww.com/10.4103/DSHMJ.DSHMJ_68_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
by: Christopher G. Rowan, et al.
Published: (2024-12-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01)

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
by: Chuntao Li, et al.
Published: (2025-07-01)

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
by: Franco Wing Tak Cheng, et al.
Published: (2024-05-01)

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
by: Ping Xu, et al.
Published: (2024-12-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
by: Sophie Marbaix, et al.
Published: (2025-02-01)

Finding of B cell epitope within polyprotein of Japanese encephalitis virus: a clue for development of new Japanese encephalitits vaccine
by: Sora Yasri, et al.
Published: (2014-06-01)

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine
by: Sora Yasri, et al.
Published: (2024-08-01)

Neurological manifestation on Leishmania siamensis: existed or not?
by: Sora Yasri, et al.
Published: (2015-04-01)

MEN1-related hyperparathyroidism: Response to cinacalcet and calcium-sensing receptor gene variant Arg990Gly
by: Sora Yasri, et al.
Published: (2019-01-01)

Dengue infection in the nervous system
by: Sora Yasri, et al.

Parasitic infections and cancer: A status report
by: Sora Yasri, et al.
Published: (2019-01-01)

Serum leptin levels and peripheral arterial stiffness in patients with type 2 diabetes
by: Sora Yasri, et al.
Published: (2019-01-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Real-World Effectiveness of Nirmatrelvir/Ritonavir in Hospitalized Older Adults with Severe Omicron COVID-19: A Retrospective Cohort Study from China
by: Chen Y, et al.
Published: (2025-06-01)

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01)

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01)

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
by: Andrea Di Lenarda, et al.
Published: (2024-08-01)

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection
by: Yun Han, et al.
Published: (2025-05-01)

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions
by: Zhiqing Fu, et al.
Published: (2025-03-01)

The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease
by: Marcin Wełnicki, et al.
Published: (2025-05-01)

Monkey Pox and Hydrocephalus
by: Sora Yasri, et al.
Published: (2023-01-01)

WWOX rs11644322 polymorphism, gemcitabine, and pancreatic cancer
by: Sora Yasri, et al.
Published: (2017-01-01)

Unexpected voriconazole toxicity due to nirmatrelvir/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring
by: J. López-Hernández, et al.
Published: (2025-06-01)

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19
by: Han Yan, et al.
Published: (2025-01-01)

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01)

Tacrolimus Toxicity in Two Renal Transplant Recipients Treated With Nirmatrelvir/Ritonavir: A Case Series
by: Meaghan Coyne, et al.
Published: (2023-03-01)

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19
by: Aisling R. Caffrey, et al.
Published: (2025-04-01)

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19
by: Carolina Moreno, et al.
Published: (2025-07-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study
by: Jingxia Chen, et al.
Published: (2025-04-01)

Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
by: Guang‐Bin Chen, et al.
Published: (2024-06-01)

A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19
by: Xiujing Zhu, et al.
Published: (2024-01-01)